Advancing the frontiers of adaptive cell therapy : A transformative mechanistic journey from preclinical to clinical settings
Copyright © 2023 Elsevier B.V. All rights reserved..
Although the concept of using the patient's immune system to combat cancer has been around for a while, it is only in recent times that substantial progress has been achieved in this field. Over the last ten years, there has been a significant advancement in the treatment of cancer through immune checkpoint blockade. This treatment has been approved for multiple types of tumors. Another approach to modifying the immune system to detect tumor cells and fight them off is adaptive cell therapy (ACT). This therapy involves using T cells that have been modified with either T cell receptors (TCR) or chimeric antigen receptors (CAR) to target the tumor cells. ACT has demonstrated encouraging outcomes in different types of tumors, and clinical trials are currently underway worldwide to enhance this form of treatment. This review focuses on the advancements that have been made in ACT from preclinical to clinical settings till now.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:125 |
|---|---|
| Enthalten in: |
International immunopharmacology - 125(2023), Pt A vom: 26. Dez., Seite 111095 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mannan, Ashi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adoptive cell therapy |
|---|
| Anmerkungen: |
Date Completed 20.11.2023 Date Revised 27.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2023.111095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363672966 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363672966 | ||
| 003 | DE-627 | ||
| 005 | 20231229123908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2023.111095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1240.xml |
| 035 | |a (DE-627)NLM363672966 | ||
| 035 | |a (NLM)37875038 | ||
| 035 | |a (PII)S1567-5769(23)01421-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mannan, Ashi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advancing the frontiers of adaptive cell therapy |b A transformative mechanistic journey from preclinical to clinical settings |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2023 | ||
| 500 | |a Date Revised 27.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Although the concept of using the patient's immune system to combat cancer has been around for a while, it is only in recent times that substantial progress has been achieved in this field. Over the last ten years, there has been a significant advancement in the treatment of cancer through immune checkpoint blockade. This treatment has been approved for multiple types of tumors. Another approach to modifying the immune system to detect tumor cells and fight them off is adaptive cell therapy (ACT). This therapy involves using T cells that have been modified with either T cell receptors (TCR) or chimeric antigen receptors (CAR) to target the tumor cells. ACT has demonstrated encouraging outcomes in different types of tumors, and clinical trials are currently underway worldwide to enhance this form of treatment. This review focuses on the advancements that have been made in ACT from preclinical to clinical settings till now | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adoptive cell therapy | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Engineered T-cells | |
| 650 | 4 | |a T-cells | |
| 650 | 4 | |a Tumor | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 700 | 1 | |a Kakkar, Chirag |e verfasserin |4 aut | |
| 700 | 1 | |a Dhiman, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Thakur Gurjeet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 125(2023), Pt A vom: 26. Dez., Seite 111095 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:125 |g year:2023 |g number:Pt A |g day:26 |g month:12 |g pages:111095 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2023.111095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 125 |j 2023 |e Pt A |b 26 |c 12 |h 111095 | ||